Canada's CareRx Q2 revenue in-line with estimates

CareRx

30/07/2025 22:45

Overview

CareRx Q2 revenue CAD 91.4 mln, largely in-line with analyst expectations, per LSEG data

Adjusted EBITDA for Q2 CAD 8.0 mln, also in-line with analyst estimates, per LSEG data

Net income for Q2 CAD 0.6 mln, improved from net loss in prior year

Outlook

CareRx anticipates growth from new beds and operational discipline

Company expects efficient scaling while maintaining quality care

Result Drivers

BED GROWTH - Increase in average number of beds serviced drove revenue growth compared to the previous quarter

PHARMACEUTICAL MIX - Revenue decline compared to the previous year due to changes in branded and generic pharmaceuticals dispensed

COST SAVINGS - Adjusted EBITDA increase attributed to efficiencies and cost-saving initiatives

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Meet
C$91.39 mln
C$91.90 mln (4 Analysts)
Q2 Net Income
C$561,000
Q2 Adjusted EBITDA
Meet
C$8 mln
C$8.10 mln (4 Analysts)
Q2 Adjusted EBITDA Margin
8.8%
Q2 EBITDA
C$6.83 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the drug retailers peer group is "buy"

Wall Street's median 12-month price target for CareRx Corp is C$3.50, about 18.6% above its July 29 closing price of C$2.85

The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release: ID:nNFC98NJ1t

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)